Evidence map›Paper›PMID 30929219›Full record

ArticleDermatology and therapy2019

Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older.

Makoto Shiragami, Akiko Mizukami, Toshihiko Kaise, Desmond Curran, Desiree Van Oorschot, Benjamin Bracke, Daisuke Watanabe

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Willingness to Pay for COVID-19 Vaccines in Japan.International journal of environmental research and public health · 2023
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Makoto ShiragamiFaculty of Pharmaceutical Sciences, Teikyo Heisei University, Tokyo, Japan.
Akiko MizukamiHealthoutcomes Department, GSK, Tokyo, Japan. akiko.mizukami@gsk.com.
Toshihiko KaiseHealthoutcomes Department, GSK, Tokyo, Japan.
Desmond CurranValue Evidence Department, GSK, Wavre, Belgium.
Desiree Van OorschotValue Evidence Department, GSK, Wavre, Belgium.
Benjamin BrackeValue Evidence Department, GSK, Wavre, Belgium.
Daisuke WatanabeDepartment of Dermatology, Aichi Medical University, Aichi, Japan.
GlaxoSmithKline (Belgium) · BEAichi Medical University · JPTeikyo Heisei University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe incidence of herpes zoster (HZ) rises steeply after the age of 50 years and the number of HZ cases and complications such as postherpetic neuralgia (PHN) is predicted to increase because of the ageing population. The objective of this study was to estimate the cost-effectiveness of recombinant zoster vaccine (RZV) compared with no vaccine for the Japanese population aged ≥ 65 years.

methodsA multi-cohort static Markov model with a cycle length of 1 year was used to follow a hypothetical cohort of 1 million people aged ≥ 65 years over their remaining lifetime. Vaccination at ≥ 65 years was used in alignment with the influenza and pneumococcal vaccines recommended from 65 years. Japan-specific data inputs for the model were obtained from local data sources. Age-stratified vaccine efficacy and waning rates were based on published clinical trial data. In the base-case analysis, vaccine coverage was assumed to be 40% with a second dose compliance of 95%. Costs and outcomes were discounted at 2% annually and the incremental cost-effectiveness ratio (ICER) was calculated from both a payer's and the societal perspective. Sensitivity analyses were carried out to explore the overall uncertainty in the model.

resultsVaccination with RZV was projected to prevent 48,943 HZ cases and 12,136 PHN cases per million people aged ≥ 65 years compared with no vaccination. The incremental costs and quality-adjusted life years (QALYs) gained were ¥9.99 billion and 2314 QALYs from a payer's perspective and ¥9.34 billion and 2314 QALYs from a societal perspective. The resulting ICERs were approximately ¥4,320,000 and ¥4,040,000 per QALY gained from a payer's and the societal perspective, respectively. The ICER remained below a willingness-to-pay threshold of ¥5,000,000 for most sensitivity analyses carried out.

conclusionVaccination against HZ with RZV would be cost-effective compared with no vaccination for the Japanese population aged ≥ 65 years.

trial registrationGSK study identifier: HO-16-17837.

fundingGlaxoSmithKline Biologicals SA.

Indexed as

Cost-effectivenessHerpes zosterIncremental cost-effectiveness ratioMarkov modelPostherpetic neuralgiaQuality-adjusted life yearsRecombinant zoster vaccineVaccination

Identifiers

PMID30929219
PMCPMC6522608
OpenAlexW2934265948

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.